Document 723-5 Filed 07/16/2007

Page 1 of 4

EXHIBIT 3

Fishman, Deborah

Fishman, Deborah From:

Friday, July 13, 2007 12:43 PM Sent:

'Julia Huston'; dcurto@mwe.com; mmayell@kayescholer.com; Keith E. Toms To:

mkendall@mwe.com; jdubrow@mwe.com; Lee Carl Bromberg Cc:

Subject: RE: Confidentiality Issues (3099/501)

Dear Julia/Keith.

I have been going through the proposal that Keith sent late Tuesday night. As a preliminary matter, the citations provided in that letter for the exhibits are incomplete and many of the exhibits that you are asking us to reduce or redact are identified in the memo, 56.1, and supporting declaration of Harvey Lodish, though not all of those references are identified in your letter. Therefore, it is taking some time to ensure that we understand the use to which the exhibits are each being put in order to understand what sort of reasonable accommodation or agreement we may be able to reach.

In addition, there is ambiguity in your request. In particular, on Exhibit 63 (item 11 in your letter), there are multiple tables called Table 11, so please indicate by production numbers the ranges for the tables and figures you would like us to redact. Please let me know as soon as possible.

Thank you, Deborah

Deborah Fishman Day Casebeer Madrid Batchelder, LLP fishmand@daycasebeer.com

From: Julia Huston [mailto:JHuston@bromsun.com]

Sent: Friday, July 13, 2007 9:25 AM

To: dcurto@mwe.com; mmayell@kayescholer.com

Cc: Fishman, Deborah; Kendall, Mike; DuBrow, Jon; Keith E. Toms; Lee Carl Bromberg

Subject: RE: Confidentiality Issues (3099/501)

Importance: High

Dear Dan.

As you know, we have been waiting for Amgen's response to Roche's proposal on 8 infringement documents since we made our written proposal on July 10. We still do not have Amgen's response. The 8 infringement documents do not raise any complex issues - for each exhibit, we will either agree that the cited portion of the exhibit may be publicly filed, or have confirmed that the proposition for which the exhibit is cited is already in another document that is or may be publicly filed.

There is no reason that we cannot reach an agreement with respect to these 8 exhibits independently of what happens with respect to the antitrust documents. Thus, I am concerned about your statement below that, in the absence of an agreement reached today, Amgen will "proceed as the Court directs." With respect to the 8 documents itemized in our written proposal on July 10, please be advised that in the event no agreement is reached, we will be making an emergency motion to strike those exhibits from the record entirely except as to certain excerpts. A copy of our motion is enclosed.

Accordingly, Amgen is hereby on notice not to file in the public record any of the 10 documents identified in our

letter of July 10, as we will be making an emergency motion to strike the first 8 exhibits and the time for us to move to seal the remaining 2 exhibits has not yet passed. It is still my hope that we can reach agreement as to the first 8 exhibits to avoid unnecessary motion practice. Please let me know if that is the case. If you do not agree to our proposal, and we are otherwise unable to reach agreement with respect to the first 8 exhibits, then we will file the emergency motion immediately.

Regards, Julia

Julia Huston

Partner

Bromberg & Sunstein LLP
Attorneys at Law
125 Summer Street
Boston, MA 02110-1618
Tel: (617) 443-9292 x 264
Fax: (617) 443-0004
jhuston@bromsun.com
www.brombergsunstein.com

This e-mail is from Bromberg & Sunstein LLP, a law firm, and may contain information that is confidential or privileged. If you are not the intended recipient, do not read, copy or distribute the e-mail or any attachments. Instead, please notify the sender and delete the e-mail and any attachments. Thank you.

From: dcurto@mwe.com [mailto:dcurto@mwe.com]

Sent: Friday, July 13, 2007 9:43 AM **To:** mmayell@kayescholer.com

Cc: dfishman@daycasebeer.com; mkendall@mwe.com; jdubrow@mwe.com; Julia Huston

Subject: Confidentiality Issues

Manvin:

Please see the attached letter regarding Amgen's proposed redactions to the summary judgment papers. I'd like to get your proposed redactions by noon so I can have sufficient time to review them before our 3:00 p.m. call. Please confirm this will happen.

In light of the upcoming hearing, we need to set some deadlines on coming to an agreement. If we can't get this done today then our plan is to proceed on the confidentiality issues as ordered by the judge.

Regards, Dan

Daniel A. Curto

McDermott Will & Emery LLP | 28 State Street, Boston, MA 02109

Office: 617-535-4036 | Fax: 617-535-3800 | Cell: 508-333-9378 | mailto:dcurto@mwe.com

www.mwe.com

Filed 07/16/2007

---- Forwarded by Daniel A Curto/BST/MWE on 07/13/2007 09:28 AM ----

Deborah Looke < DLooke@mwe.com>

To Dan Curto <DCurto@mwe.com>

07/13/2007 10:36 AM

Subject letter to mayell

This E-mail includes attached file(s) sent from "RNP7D629D" (Aficio 1060).

Scan Date: 07.13.2007 09:36:24 (-0500)

Queries to: sreed@mwe.com

IRS Circular 230 Disclosure: To comply with requirements imposed by the IRS, we inform you that any U.S. federal tax advice contained herein (including any attachments), unless specifically stated otherwise, is not

intended or written to be used, and cannot be used, for the purposes of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter herein.

This message is a PRIVATE communication. This message and all attachments are a private communication sent by a law firm and may be confidential or protected by privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the information contained in or attached to this message is strictly prohibited. Please notify the sender of the delivery error by replying to this message, and then delete it from your system. Thank you.

Please visit http://www.mwe.com/ for more information about our Firm.